Advertisement

Bone Sarcomas

  • Gislaine Fernandes Silva
  • Daiane Pereira Guimarães
  • Hakaru Tadokoro
  • Ramon Andrade De MelloEmail author
Chapter

Abstract

Bone sarcomas are primary malignant tumors of osteoid producing cells adjacent to growth plates, which arise more frequently in long bones (Clark J, Rocques PJ, Crew AJ et al: Nat Genet 7:502–508, 1994). Unlike soft tissue sarcomas, which have a wide variety of histological subtypes, bone sarcomas have only three distinct categories: chondrosarcoma, Ewing’s sarcoma and osteosarcoma. Bone sarcomas are more common in children and young adults, with some exceptions in later years. The management of bone sarcomas varies considerably, according to histology, degree and stage (Devita H: Rosemberg’s cancer: principles & practice of oncology. In: VT DV Jr, Lawewnce TS, Rosemberg SA (eds) Chapter 121 with 404 contributing authors, 10th edn. LWW, New York, 2014).

Keywords

Bone sarcoma Chemotherapy Radiotherapy 

References

  1. 1.
    Clark J, Rocques PJ, Crew AJ et al (1994) Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7:502–508CrossRefGoogle Scholar
  2. 2.
    Devita H (2014) Rosemberg’s cancer: principles & practice of oncology. In: VT DV Jr, Lawewnce TS, Rosemberg SA (eds) Chapter 121 with 404 contributing authors, 10th edn. LWW, New YorkGoogle Scholar
  3. 3.
    Siegel R, Ma J, Zou Z et al (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ottaviani G, Jaffe N (2009) The etiology of osteosarcoma. Cancer Treat Res 152:15–32CrossRefGoogle Scholar
  5. 5.
    Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 71:747–752CrossRefGoogle Scholar
  6. 6.
    Hansen MF, Koufos A, Gallie BL et al (1985) Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A 82:6216–6260CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Shaylor PJ, Peake D, Grimer RJ et al (1999) Paget’s osteosarcoma – no cure in sight. Sarcoma 1999;3:191–192 Shaylor PJ, Peake D, Grimer RJ, et al. Paget’s osteosarcoma – no cure in sight. Sarcoma 3:191–192CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Witkin GB, Guilford WB, Siegal GP (1986) Osteogenic sarcoma and soft tissue myxoma in a patient with fibrous dysplasia and hemoglobins JBaltimore and S. Clin Orthop Relat Res 204:245–252Google Scholar
  9. 9.
    Horvai A, Unni KK (2006) Premalignant conditions of bone. J Orthop Sci 11:412–423CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Domson GF, Shahlee A, Reith JD et al (2009) Infarct-associated bone sarcomas. Clin Orthop Relat Res 467:1820–1825CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Meyers PA, Gorlick R (1997) Osteosarcoma. Pediatr Clin N Am 44:973–989CrossRefGoogle Scholar
  12. 12.
    Thorpe WP, Reilly JJ, Rosenberg SA (1979) Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 43:2178–2181CrossRefGoogle Scholar
  13. 13.
    Mialou V, Philip T, Kalifa C et al (2005) Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer 104:1100–1109CrossRefGoogle Scholar
  14. 14.
    Sajadi KR, Heck RK, Neel MD et al (2004) The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop Relat Res 426:92–96CrossRefGoogle Scholar
  15. 15.
    Jeffree GM, Price CH, Sissons HA (1975) The metastatic patterns of osteosarcoma. Br J Cancer 32:87–107CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Podoloff DA, Advani RH, Allred C et al (2007) NCCN task force report: PET/CT scanning in cancer. J Natl Compr Cancer Netw 5:S1–S22CrossRefGoogle Scholar
  17. 17.
    Skrzynski MC, Biermann JS, Montag A et al (1996) Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. J Bone Joint Surg Am 78-A:644–649CrossRefGoogle Scholar
  18. 18.
    American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer Science+Business Media, LLCGoogle Scholar
  19. 19.
    Fletcher CDM, Bridge JA, Hogendoorn P et al (eds) (2013) WHO classification of tumors of soft tissue and bone, 4th edn. IARC Press, LyonGoogle Scholar
  20. 20.
    Evans SC, Lozano G (1997) The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 3:390–395CrossRefGoogle Scholar
  21. 21.
    Leerapun T, Hugate RR, Inwards CY et al (2007) Surgical management of conventional grade I chondrosarcoma of long bones. Clin Orthop Relat Res 463:166PubMedGoogle Scholar
  22. 22.
    Normand AN, Ballo MT, Yasko AW et al (2006) Palliative radiation therapy for chondrosarcoma (abstract). Proc Connect Tissue Oncol Soc 12:745aGoogle Scholar
  23. 23.
    Wyman JJ, Hornstein AM, Meitner PA et al (1999) Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J Orthop Res 17:935–940CrossRefGoogle Scholar
  24. 24.
    Van Oosterwijk JG, Herpers B, Meijer D et al (2012) Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol 23:1617–1626CrossRefGoogle Scholar
  25. 25.
    Van Maldegem AM, Gelderblom H, Palmerini E, Dijkstra SD et al (2014) Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer 120(20):3159–3164CrossRefGoogle Scholar
  26. 26.
    Italiano A, Mir O, Cioffi A, Palmerini E et al (2013 Nov) Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol 24(11):2916–2922CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    La Rocca RV, Morgan KW, Paris K, Baeker TR (1999) Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy. J Neuro-Oncol 41(3):281–283CrossRefGoogle Scholar
  28. 28.
    Turc-Carel C, Philip I, Berger MP et al (1984) Chromosome study of Ewing’s sarcoma (ES) cell lines. Consistency of a reciprocal translocation t (11,22)(q24;q12). Cancer Genet Cytogenet 12:1–19CrossRefGoogle Scholar
  29. 29.
    Fizazi K, Dohollou N, Blay JY et al (1998) Ewing’s family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol 16:3736–3743CrossRefGoogle Scholar
  30. 30.
    Bacci G, Picci P, Gitelis S et al (1982) The treatment of localized Ewing’s sarcoma: the experience at the Istituto Rizzoli in 163 cases treated with and without adjuvant chemotherapy. Cancer 49:1561–1570CrossRefGoogle Scholar
  31. 31.
    Womer RB, West DC, Krailo MD et al (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a repor from the Children’s Oncology Group. J Clin Oncol 30:4148–4154CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Werier J, Yao X, Caudrelier JM et al (2016) A systematic review of optimal treatment strategies for localized Ewing’s sarcoma of bone after neo-adjuvant chemotherapy. Surg Oncol 25:16–23CrossRefGoogle Scholar
  33. 33.
    Paulussen M, Ahrens S, Craft AW et al (1998) Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol 16:3044–3052CrossRefGoogle Scholar
  34. 34.
    Miser JS, Krailo MD, Tarbell NJ et al (2004) Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol 22(14):2873–2876CrossRefGoogle Scholar
  35. 35.
    Hayes FA, Thompson EI, Kumar M et al (1987) Long-term survival in patients with Ewing’s sarcoma relapsing after completing treatment. Med Pediatr Oncol 15:254–256CrossRefGoogle Scholar
  36. 36.
    Ferrari S, Brach del Prever A, Palmerini E et al (2009) Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer 52:581–584CrossRefGoogle Scholar
  37. 37.
    Navid F, Reikes Willert J, McCarville MB et al (2008) Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113:419–425CrossRefGoogle Scholar
  38. 38.
    Saylors RL III, Stine KC, Sullivan J et al (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II Study. J Clin Oncol 19:3463–3469CrossRefGoogle Scholar
  39. 39.
    Wagner LM, Crews KR, Iacono LC et al (2004) Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10:840–848CrossRefGoogle Scholar
  40. 40.
    McKenna R, Schwinn C, Soong K et al (1966) Sarcomas of the osteogenic series (osteosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone): an analysis of 552 cases. J Bone Joint Surg Am 48:1–26CrossRefGoogle Scholar
  41. 41.
    Smith MA, Gurney JG, Ries LA (1999) Cancer in adolescents 15 to 19 years old. In: Ries LA, Smith MAS, Gurney JG et al (eds) Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995 (Pub #99-4649). SEER Program, National Cancer Institute, BethesdaGoogle Scholar
  42. 42.
    Klein MJ, Siegal GP (2006 Apr) Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 125(4):555–581CrossRefGoogle Scholar
  43. 43.
    Jaffe N, Carrasco H, Raymond K et al (2002) Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 95:2202–2210CrossRefGoogle Scholar
  44. 44.
    Peabody TD, Gibbs CP Jr, Simon MA (1998) Evaluation and staging of musculoskeletal neoplasms. J Bone Joint Surg Am 80:1204–1218CrossRefGoogle Scholar
  45. 45.
    Bruland OS, Høifødt H, Saeter G et al (2005) Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 11:4666–4673CrossRefGoogle Scholar
  46. 46.
    Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574–1580CrossRefGoogle Scholar
  47. 47.
    Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011CrossRefGoogle Scholar
  48. 48.
    Souhami RL, Craft AW, Van der Eijken JW et al (1997) Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350:911–917CrossRefGoogle Scholar
  49. 49.
    Ciernik IF, Niemierko A, Harmon DC et al (2011) Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 117:4522–4530CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Petrilli AS, de Camargo B, Filho VO et al (2006) Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 24:1161–1168CrossRefGoogle Scholar
  51. 51.
    Bacci G, Briccoli A, Ferrari S et al (2000) Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 7:339PubMedGoogle Scholar
  52. 52.
    Goorin AM, Harris MB, Bernstein M et al (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20:426–433CrossRefGoogle Scholar
  53. 53.
    Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J (1994 Dec) Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 12(12):2614–2620CrossRefGoogle Scholar
  54. 54.
    Mahajan A, Woo SY, Kornguth DG et al (2008) Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer 50:976–982CrossRefGoogle Scholar
  55. 55.
    Kung F, Hayes FA, Krischer J et al (1988) Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Investig New Drugs 6:31CrossRefGoogle Scholar
  56. 56.
    Rodríguez-Galindo C, Daw NC, Kaste SC et al (2002) Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 24:250–255CrossRefGoogle Scholar
  57. 57.
    Fox E, Patel S, Wathen JK et al (2012) Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 17:321–e329CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gislaine Fernandes Silva
    • 1
  • Daiane Pereira Guimarães
    • 2
  • Hakaru Tadokoro
    • 3
  • Ramon Andrade De Mello
    • 4
    • 5
    Email author
  1. 1.Department of Medical OncologyFederal University of São PauloSão PauloBrazil
  2. 2.Clinical Oncology Medical ProgramFederal University of São Paulo – UNIFESPSão PauloBrazil
  3. 3.Division of Medical Oncology, Escola Paulista de MedicinaFederal University of São PauloSão PauloBrazil
  4. 4.Division of Medical OncologyFederal University of São Paulo (UNIFESP) & Hospital Israelita Albert EinsteinSão PauloBrazil
  5. 5.Department of Biomedical Sciences and MedicineUniversity of AlgarveFaroPortugal

Personalised recommendations